Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03748641 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer

Study acronym: MAGNITUDE
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 94 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Study sites revised (318)
  2. Lead sponsor: Janssen Research & Development, LLC to Janssen Research & Development, LLC Completion pushed from Feb 27, 2027 to Dec 31, 2027 · Study sites revised (318) Show 2 more changesShow less
    • Completion pushed from Feb 27, 2027 to Dec 31, 2027
    • Study sites revised (318)
  3. 2 versions Re-verified since Jul 2, 2026, no change to tracked fieldsv91-v92
  4. Study sites revised (318)v90 See this version in full on ClinicalTrials.gov ↗
  5. Re-verified, no change to tracked fieldsv89
Show 44 earlier versionsHide 44 earlier versions
  1. Study sites revised (318)v88 See this version in full on ClinicalTrials.gov ↗
  2. Re-verified, no change to tracked fieldsv87
  3. Site details revised at 1 of 318 sitesv86
  4. Study sites revised (318)v85 See this version in full on ClinicalTrials.gov ↗
  5. 6 versions Re-verified since Jul 17, 2025, no change to tracked fieldsv79-v84
  6. Study sites revised (318)v78 See this version in full on ClinicalTrials.gov ↗
  7. Completion date: Feb 19, 2027 to Feb 27, 2027 Study sites revised (318)v77 Show 1 more changeShow less
    • Study sites revised (318)

    See this version in full on ClinicalTrials.gov ↗

  8. Completion date: Mar 19, 2027 to Feb 19, 2027v76
  9. Re-verified, no change to tracked fieldsv75
  10. Completion date: Feb 19, 2027 to Mar 19, 2027v74
  11. Study sites revised (318)v73 See this version in full on ClinicalTrials.gov ↗
  12. Study sites revised (318)v72 See this version in full on ClinicalTrials.gov ↗
  13. Re-verified, no change to tracked fieldsv71
  14. Study sites revised (318)v70 See this version in full on ClinicalTrials.gov ↗
  15. 2 versions Re-verified since Sep 10, 2024, no change to tracked fieldsv68-v69
  16. Study sites revised (318)v67 See this version in full on ClinicalTrials.gov ↗
  17. Study Identification, Study Status, Study Description, Arms and Interventionsv66
  18. Primary endpoints: 1 to 2 Study sites revised (318)v65 Show 1 more changeShow less
    • Study sites revised (318)

    See this version in full on ClinicalTrials.gov ↗

  19. Study sites revised (318)v64 See this version in full on ClinicalTrials.gov ↗
  20. Study sites revised (318)v63 See this version in full on ClinicalTrials.gov ↗
  21. Study sites revised (318)v62 See this version in full on ClinicalTrials.gov ↗
  22. Study sites revised (318)v61 See this version in full on ClinicalTrials.gov ↗
  23. Study sites revised (318)v60 See this version in full on ClinicalTrials.gov ↗
  24. Study sites revised (318)v59 See this version in full on ClinicalTrials.gov ↗
  25. Study sites revised (318)v58 See this version in full on ClinicalTrials.gov ↗
  26. Study sites revised (318)v57 See this version in full on ClinicalTrials.gov ↗
  27. Study sites revised (318)v56 See this version in full on ClinicalTrials.gov ↗
  28. Results first posted: Oct 4, 2023 Study sites revised (318)v55 Show 1 more changeShow less
    • Study sites revised (318)

    See this version in full on ClinicalTrials.gov ↗

  29. Re-verified, no change to tracked fieldsv54
  30. Study Status, Contacts/Locationsv53
  31. Study sites revised (318)v52 See this version in full on ClinicalTrials.gov ↗
  32. Study sites revised (318)v51 See this version in full on ClinicalTrials.gov ↗
  33. Study sites revised (318)v50 See this version in full on ClinicalTrials.gov ↗
  34. Study sites revised (318)v49 See this version in full on ClinicalTrials.gov ↗
  35. Study sites revised (318)v48 See this version in full on ClinicalTrials.gov ↗
  36. Study sites revised (318)v47 See this version in full on ClinicalTrials.gov ↗
  37. Re-verified, no change to tracked fieldsv46
  38. Study sites revised (318)v45 See this version in full on ClinicalTrials.gov ↗
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the effectiveness of niraparib in combination with abiraterone acetate plus prednisone (AAP) compared to AAP and placebo.
Trial Details
NCT Number NCT03748641
Lead Sponsor Janssen Research & Development, LLC
Conditions Castration-Resistant Prostatic Cancer
Enrollment 765 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov